mechlorethamine has been researched along with paclitaxel in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (44.44) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Demers, GW; Galloway, DA; Hawkins, DS | 1 |
| Huang, L; Son, K | 1 |
| Andres, JL; Fan, S; Goldberg, ID; Lamszus, K; Rosen, EM; Turkel, GJ; Twu, NF; Wang, JA; Yuan, RQ | 1 |
| Hait, WN; Liao, J; Medina, DJ; Vassil, AD; Yang, GY; Yang, JM | 1 |
| Ling, MT; Wang, X; Wong, YC; Zhang, X | 1 |
| Higgins, LS; Orlowski, RZ; Shi, YY; Small, GW | 1 |
| García-Sanz, R; González-López, TJ; Graciani, IF; Hermida, G; San Miguel, JF; Vázquez, L | 1 |
1 review(s) available for mechlorethamine and paclitaxel
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
8 other study(ies) available for mechlorethamine and paclitaxel
| Article | Year |
|---|---|
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents.
Topics: Animals; Antineoplastic Agents; Aphidicolin; Carboplatin; Cell Cycle; Cell Line, Transformed; Cell Survival; Cell Transformation, Neoplastic; Cells, Cultured; Cisplatin; Embryo, Mammalian; Fibroblasts; Genes, p53; Genes, Retinoblastoma; Heterozygote; Homozygote; Humans; Infant, Newborn; Kinetics; Male; Mechlorethamine; Melphalan; Mice; Oncogene Proteins, Viral; Paclitaxel; Papillomaviridae; Papillomavirus E7 Proteins; Repressor Proteins; Skin; Time Factors | 1996 |
Factors influencing the drug sensitization of human tumor cells for in situ lipofection.
Topics: Animals; Antineoplastic Agents; Bleomycin; Cation Exchange Resins; Chloramphenicol O-Acetyltransferase; Cholesterol; Cisplatin; DNA; Female; Head and Neck Neoplasms; Lipids; Liposomes; Lung Neoplasms; Mechlorethamine; Mice; Mice, SCID; Ovarian Neoplasms; Paclitaxel; Phosphatidylethanolamines; Transfection | 1996 |
Regulation of BRCA1 and BRCA2 expression in human breast cancer cells by DNA-damaging agents.
Topics: Antineoplastic Agents; Apoptosis; BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Cell Cycle; Cell Division; Cell Survival; Doxorubicin; Female; Humans; Intercalating Agents; Mechlorethamine; Neoplasm Proteins; Paclitaxel; RNA, Messenger; Transcription Factors; Tumor Cells, Cultured; Ultraviolet Rays; Vincristine | 1998 |
Treatment of multidrug resistant (MDR1) murine leukemia with P-glycoprotein substrates accelerates the course of the disease.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Membrane; Cell Movement; Disease Progression; Drug Resistance, Neoplasm; Female; Flupenthixol; Humans; Hydrogen-Ion Concentration; Leukemia P388; Liver Neoplasms; Mechlorethamine; Mice; Neoplasm Invasiveness; Neoplasm Transplantation; Paclitaxel; Survival Rate; Tumor Cells, Cultured; Vincristine | 1999 |
Evidence of a novel antiapoptotic factor: role of inhibitor of differentiation or DNA binding (Id-1) in anticancer drug-induced apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Carcinoma, Hepatocellular; Catechin; Cell Line, Tumor; Cell Survival; Cisplatin; Down-Regulation; Doxorubicin; Etoposide; Female; HeLa Cells; Humans; Inhibitor of Differentiation Protein 1; Liver Neoplasms; Male; Mechlorethamine; Methotrexate; Mitomycin; Nasopharyngeal Neoplasms; Paclitaxel; Prostatic Neoplasms; Vincristine | 2007 |
Mitogen-activated protein kinase phosphatase-1 is a mediator of breast cancer chemoresistance.
Topics: Apoptosis; Breast Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; Doxorubicin; Drug Interactions; Drug Resistance, Neoplasm; Dual Specificity Phosphatase 1; Enzyme Activation; Humans; Immediate-Early Proteins; Indoles; MAP Kinase Kinase 4; Mechlorethamine; p38 Mitogen-Activated Protein Kinases; Paclitaxel; Phosphoprotein Phosphatases; Protein Phosphatase 1; Protein Tyrosine Phosphatases | 2007 |
The combination of thalidomide, cyclophosphamide and dexamethasone is potentially useful in highly resistant Hodgkin's lymphoma.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dacarbazine; Deoxycytidine; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Hodgkin Disease; Humans; Male; Mechlorethamine; Melphalan; Organoplatinum Compounds; Paclitaxel; Peripheral Blood Stem Cell Transplantation; Prednisolone; Prednisone; Procarbazine; Remission Induction; Rituximab; Salvage Therapy; Thalidomide; Topotecan; Transplantation, Autologous; Vidarabine; Vinblastine; Vincristine | 2010 |